pubmed semaglutide Efficacy and safety of once-weekly 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial A Review on Semaglutide: An

Semaglutide is an injectable drug gaining popularity for its potential to help people manage weight-related health concerns

Dr Reddys and Nestl Health Science have launched Celevida GLP Plus in the domestic market

Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today.

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.

Cost Snapshot: $105,500/kg API production cost $175 million capital investment for a 500 kg/year facility Despite being a marvel of peptide engineering, semaglutides affordability challenge is real and urgent